Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanquin
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.
Recent portrayals of drug GMP enforcement activity in reports to stockholders ran the gamut from acknowledging the likelihood of adverse financial impacts to suggesting that remediation in response to 483s must be going well because there hasn’t been a warning letter.
START-UP’s monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical device sectors.
- Academic and Research Institutions
- Other Names / Subsidiaries
- Sanquin Blood Supply Foundation
- Sanquin Plasma Products B.V
- Sanquin Oy